

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if known</b>	
		<b>Application Number</b>	10/722,357 Conf. No.: 4705
		<b>Filing Date</b>	November 24, 2003
		<b>First Named Inventor</b>	Michela Gallagher
		<b>Art Unit</b>	1611
<b>Examiner Name</b>	Kyle A. Purdy		
<b>Attorney Docket Number</b>	JHUC-008-101		
<b>Sheet</b>	1	<b>of</b>	2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number – Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Allain <i>et al.</i> , "Treatment of the Mild Cognitive Impairment (MCI)," <i>Human Psychopharmacology: Clinical and Experimental</i> , 22: 189-197 (2007).	
		Alsop <i>et al.</i> , "Hippocampal Hyperperfusion in Alzheimer's Disease," <i>NeuroImage</i> , 42: 1267-1274 (2008)	
		Dickerson <i>et al.</i> , "Increased Hippocampal Activation in Mild Cognitive Impairment Compared to Normal Aging and AD," <i>Neurology</i> , 65: 404-411 (2005)	
		Fernandez <i>et al.</i> , "Mild Cognitive Impairment in Parkinson's Disease: The Challenge and the Promise," <i>Neuropsychiatric Disease and Treatment</i> , 1: 37-50 (2005)	
		Grundman <i>et al.</i> , "Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials," <i>Archives of Neurology</i> , 61: 59-66 (2004)	
		Herrmann <i>et al.</i> , "Pharmacologic Management of Neuropsychiatric Symptoms of Alzheimer Disease," <i>The Canadian Journal of Psychiatry</i> , 52: 630-646 (2007)	
		Petersen <i>et al.</i> , "Mild Cognitive Impairment," <i>Archives of Neurology</i> , 56: 303-308 (1999)	
		Petersen <i>et al.</i> , "Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment," <i>The New England Journal of Medicine</i> , 352: 2379-2388 (2005)	
		Porsteinsson <i>et al.</i> , "Placebo-Controlled Study of Divalproex Sodium for Agitation in Dementia," <i>American Journal of Geriatric Psychiatry</i> , 9: 58-66 (2001)	

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if known</b>	
		<b>Application Number</b>	10/722,357 Conf. No.: 4705
		<b>Filing Date</b>	November 24, 2003
		<b>First Named Inventor</b>	Michela Gallagher
		<b>Art Unit</b>	1611
<b>Examiner Name</b>	Kyle A. Purdy		
<b>Attorney Docket Number</b>	JHUC-008-101		
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Rapp <i>et al.</i> , "Preserved Neuron Number in the Hippocampus of Aged Rats with Spatial Learning Deficits," <i>Proceedings of the National Academy of Sciences USA</i> , 93: 9926-9930 (1996)	
		Roberts <i>et al.</i> , "The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics," <i>Neuroepidemiology</i> , 30: 58-69 (2008)	
		Sival <i>et al.</i> , "Sodium Valproate in the Treatment of Aggressive Behavior in Patients with Dementia--A Randomized Placebo Controlled Clinical Trial," <i>International Journal of Geriatric Psychiatry</i> , 17: 579-85 (2002)	
		Tariot <i>et al.</i> , "Alzheimer's Disease Cooperative Study: Chronic Valproate Therapy To Attenuate The Clinical Progression Of Alzheimer's Disease," 2009 International Conference on Alzheimer's Disease	
		Tariot <i>et al.</i> , "Divalproex Sodium in Nursing Home Residents with Possible or Probable Alzheimer Disease Complicated by Agitation," <i>American Journal of Geriatric Psychiatry</i> , 13: 942-49 (2005)	
		Tariot <i>et al.</i> , "Safety and Tolerability of Divalproex Sodium in the Treatment of Signs and Symptoms of Mania in Elderly Patients with Dementia: Results of a Double-Blind, Placebo-Controlled Trial," <i>Current Therapeutic Research</i> , 62: 51-67 (2001)	
		Thal <i>et al.</i> , "Randomized, Double-blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment," <i>Neuropsychopharmacology</i> , 30: 1204-1215 (2005)	
		Wilson <i>et al.</i> , "Neurocognitive Aging: Prior Memories Hinder New Hippocampal Encoding," <i>Trends Neuroscience</i> , 29: 662-670 (2006)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.